Section 54
Chapter 53,379

Genetic and pharmacological reactivation of the mammalian inactive X chromosome

Bhatnagar, S.; Zhu, X.; Ou, J.; Lin, L.; Chamberlain, L.; Zhu, L.J.; Wajapeyee, N.; Green, M.R.

Proceedings of the National Academy of Sciences of the United States of America 111(35): 12591-12598


ISSN/ISBN: 1091-6490
PMID: 25136103
DOI: 10.1073/pnas.1413620111
Accession: 053378817

Download citation:  

X-chromosome inactivation (XCI), the random transcriptional silencing of one X chromosome in somatic cells of female mammals, is a mechanism that ensures equal expression of X-linked genes in both sexes. XCI is initiated in cis by the noncoding Xist RNA, which coats the inactive X chromosome (Xi) from which it is produced. However, trans-acting factors that mediate XCI remain largely unknown. Here, we perform a large-scale RNA interference screen to identify trans-acting XCI factors (XCIFs) that comprise regulators of cell signaling and transcription, including the DNA methyltransferase, DNMT1. The expression pattern of the XCIFs explains the selective onset of XCI following differentiation. The XCIFs function, at least in part, by promoting expression and/or localization of Xist to the Xi. Surprisingly, we find that DNMT1, which is generally a transcriptional repressor, is an activator of Xist transcription. Small-molecule inhibitors of two of the XCIFs can reversibly reactivate the Xi, which has implications for treatment of Rett syndrome and other dominant X-linked diseases. A homozygous mouse knockout of one of the XCIFs, stanniocalcin 1 (STC1), has an expected XCI defect but surprisingly is phenotypically normal. Remarkably, X-linked genes are not overexpressed in female Stc1(-/-) mice, revealing the existence of a mechanism(s) that can compensate for a persistent XCI deficiency to regulate X-linked gene expression.

PDF emailed within 0-6 h: $19.90